International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
about
Clinical development of Ebola vaccinesOncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsAdvances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesA global approach to HIV-1 vaccine developmentPre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responsesA nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungsAd35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus speciesLow seroprevalent species D adenovirus vectors as influenza vaccines.Adenoviral vectors as novel vaccines for influenza.Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.Nonreplicating vectors in HIV vaccines.New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors.Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectorsThe influence of delivery vectors on HIV vaccine efficacyInfection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques.First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity.The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses.A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.Role of adenoviruses in obesity.Novel vaccine vectors for HIV-1.HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humansA Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancerBolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola VaccineA Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria VaccineThe number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexesPreexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys.Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys.Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsAntigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform.Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous deliveryA serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011
P2860
Q26775792-E1B74DCD-39EE-4CE0-8498-90D6424A6BE3Q26776553-30174AA4-28BA-402E-AB5A-0F6A8F92D4CCQ26782083-63FC6737-B8D8-4C5A-B5A1-739EC9721F28Q27013568-355FA154-BF1F-4CAB-B626-E69CC9A28998Q27024614-A95DF562-ECA4-4267-BB0C-42CBE0DD6405Q27304910-203288D2-EE06-4BC9-BB5A-907620F10B7AQ28396228-ED2E3031-A567-46CC-B205-453A512C539DQ28485505-333082BA-8A1B-4AF0-B9A7-797A4F838CA4Q30353263-00F3053D-F88D-4A94-A09F-D4A6B855B132Q30370445-DFEBCE4B-D6D4-4A02-8981-9376B745F906Q30422006-14B23C9B-95F7-48B3-BA9F-FAC6E801765EQ33693891-3177F18E-9919-42DA-8893-C1CE75BD9C47Q33868760-97C175D6-2356-441F-926D-4E7C079EFD5DQ34033882-73255072-B403-41ED-92F0-45625ECBCAF4Q34057708-5F38911E-D4D5-4B55-AB32-F3CDA1F35D44Q34077543-D8EE8990-A2F5-4B38-AC39-5A7FC194B396Q34155550-EDDEF600-E8B6-425A-BED9-39AF0F75243DQ34209026-65263940-12E4-49CF-8C4A-3D4F5379C31FQ34262192-1718577D-E637-4FEF-9FFE-9991CC670C8BQ34341345-984F289D-DF3A-4D93-B795-1AAE87683C03Q34369139-301778AD-EA8F-4E56-883C-39B8653F2C08Q34493305-381D4C36-5322-4AD5-B9EE-A2A8CD4DCF41Q34541191-93F801E7-399E-4AB9-89CC-05753B391831Q34789269-D1AF41D9-11D0-47B2-82BD-4DEC802631C8Q34991437-9ADFE08B-EBC4-4995-8BC6-61B8A4DC6211Q35055188-14AEA3AC-0645-4DC3-9085-BB647EBA107AQ35593139-5198C23D-8430-4A3A-8301-3B7111C3E60EQ35864700-59451A7B-332A-4D98-AD89-D2AE19783C68Q35917496-36A1A111-4893-4012-8955-5E848140B2CEQ36003208-C2D63876-9230-462E-A16A-02D153A5A7DAQ36023055-56B17559-44CC-4E1D-B1E1-3965DA4ED450Q36154059-F4A0E584-CEE5-4F2B-BE03-BE203D9DF92DQ36171869-AD932367-AF30-4862-A32F-0C01E199E15EQ36192765-8EE04CE7-FB78-4654-A42B-811F963BF7F4Q36276518-9792FD5A-8FA1-415A-87FC-6B58FDAFFEB9Q36288468-629DFB55-38DC-4C03-B66A-F54CAC20A672Q36330007-150722CB-9210-48EC-8E78-B454F33B5C37Q36339059-4E02958A-D30C-4055-A33C-8C93616867ADQ36445557-A500F593-2338-4770-80E8-1FBB85D8A2A5Q36448142-5E4CEF31-F61D-464B-9958-A593C4BB40DB
P2860
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
International seroepidemiology ...... ediatric and adult populations
@ast
International seroepidemiology ...... ediatric and adult populations
@en
type
label
International seroepidemiology ...... ediatric and adult populations
@ast
International seroepidemiology ...... ediatric and adult populations
@en
prefLabel
International seroepidemiology ...... ediatric and adult populations
@ast
International seroepidemiology ...... ediatric and adult populations
@en
P2093
P2860
P50
P1433
P1476
International seroepidemiology ...... ediatric and adult populations
@en
P2093
Angela Carville
Athmanundh Dilraj
David Ng'ang'a
Faruk Sinangil
Gerrit J Weverling
Glenda E Gray
Guy de Bruyn
Hannah Kibuuka
Jill Gilmour
John Hural
P2860
P304
P356
10.1016/J.VACCINE.2011.05.025
P407
P50
P577
2011-05-25T00:00:00Z